Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Collyar: What's In It for Patients?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame healt...

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Jan

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Collyar: What's In It for Patients?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Patient-Reported Outcomes With Triplet Therapy for Newly Diagnosed Multiple Myeloma

Surgical Intervention May Offer Survival Advantage for Certain Patients With Metastatic Breast Cancer

Do Adult-Onset Cancer Survivors Have a Higher Risk of Developing a Subsequent Malignancy

Adjuvant Gefitinib vs Vinorelbine/Cisplatin in Stage II–IIIA EGFR-Mutant NSCLC

Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer